Reyvow 50 MG Oral Tablet

RxCUI: 2256947
RxNorm name: Reyvow 50 MG Oral Tablet
Display name: Reyvow 50 MG Oral Tablet
Full name: Reyvow 50 MG Oral Tablet
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:15

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Reyvow	LASMIDITAN	Eli Lilly and Company	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	2026-01-08	Warnings, Adverse reactions	Exact identifier rxcui: 2256947

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
aea3358c-ff41-4490-9e6d-c7bf7b3de13f	REYVOW 50 MG Oral Tablet [PSN] · lasmiditan 50 MG Oral Tablet [Reyvow] [SBD] · Reyvow 50 MG Oral Tablet [SY]	3	15	These highlights do not include all the information needed to use REYVOW safely and effectively. See full prescribing information for REYVOW. REYVOW (lasmiditan) tablets, for oral use, CV Initial U.S. Approval: 2020	20241113